Erosive arthritis in a patient with pycnodysostosis: An experiment of nature

Arthritis and Rheumatism

Volumn 58, Issue 11, 2008, Pages 3394-3401

  Ainola, Mari ^a   Valleala, Heikki ^a   Nykänen, Pekka ^b   Risteli, Juha ^c   Hanemaaijer, Roeland ^d   Konttinen, Yrjö T ^a,e  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Finnish Rheumatism Association   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d TNO   (Netherlands)

^e University of Tampere   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCITONIN RECEPTOR; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; FOLIC ACID; HYDROXYCHLOROQUINE; KETOPROFEN; MATRIX METALLOPROTEINASE; MESSENGER RNA; METHOTREXATE; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BONE DEFECT; BONE EROSION; CASE REPORT; COLLAGEN DEGRADATION; CONTROLLED STUDY; DRUG WITHDRAWAL; DYSOSTOSIS; FEMALE; HAND RADIOGRAPHY; HUMAN; HUMAN CELL; MONOCYTE; MULTINUCLEAR CELL; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PYKNODYSOSTOSIS; RASH; SYNOVITIS;

ACID PHOSPHATASE; ARTHRITIS, PSORIATIC; BONE RESORPTION; CATHEPSINS; CELLS, CULTURED; DYSOSTOSES; FEMALE; HUMANS; MIDDLE AGED; MONOCYTES; OSTEOCLASTS; RECEPTORS, CALCITONIN;

EID: 55849131407     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.23996     Document Type: Article

References (34)

1. Bromme D, Okamoto K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler 1995;376:379-84.
2. Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun 1995;206:89-96.
3. Li YP, Alexander M, Wucherpfennig AL, Yelick P, Chen W, Stashenko P. Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas. J Bone Miner Res 1995;10:1197-202.
4. Shi GP, Chapman HA, Bhairi SM, DeLeeuw C, Reddy VY, Weiss SJ. Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. FEBS Lett 1995;357:129-34.
5. Inui T, Ishibashi O, Inaoka T, Origane Y, Kumegawa M, Kokubo T, et al. Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J Biol Chem 1997;272:8109-12.
6. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996;271:12511-6.
7. Littlewood-Evans A, Kokubo T, Ishibashi O, Inaoka T, Wlodarski B, Gallagher JA, et al. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 1997;20:81-6.
8. Yamaza T, Goto T, Kamiya T, Kobayashi Y, Sakai H, Tanaka T. Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur. Bone 1998;23:499-509.
9. Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998;273:32347-52.
10. Bromme D, Okamoto K, Wang BB, Biroc S. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts: functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 1996;271:2126-32.
11. Konttinen YT, Mandelin J, Li TF, Salo J, Lassus J, Liljestrom M, et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum 2002;46:953-60.
12. Morko JP, Soderstrom M, Saamanen AM, Salminen HJ, Vuorio EI. Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis. Ann Rheum Dis 2004;63:649-55.
13. Steinmeyer J, Konttinen YT. Oral treatment options for degenerative joint disease: presence and future. Adv Drug Deliv Rev 2006;58:168-211.
14. Salminen-Mankonen HJ, Morko J, Vuorio E. Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 2007;8:315-23.
15. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 2007;13:387-403.
16. Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA. Osteoarthritis: an untreatable disease? Nat Rev Drug Discov 2005;4:331-44.
17. Saftig P, Hunziker E, Everts V, Jones S, Boyde A, Wehmeyer O, et al. Functions of cathepsin K in bone resorption: lessons from cathepsin K deficient mice. Adv Exp Med Biol 2000;477:293-303.
18. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999;14:1654-63.
19. Morko J, Kiviranta R, Joronen K, Saamanen AM, Vuorio E, Salminen-Mankonen H. Spontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin K. Arthritis Rheum 2005;52:3713-7.
20. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236-8.
21. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-40.
22. Lindeman JH, Hanemaaijer R, Mulder A, Dijkstra PD, Szuhai K, Bromme D, et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 2004;165:593-600.
23. Mandelin J, Liljestrom M, Li TF, Ainola M, Hukkanen M, Salo J, et al. Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation. J Biomed Mater Res B Appl Biomater 2005;74:582-8.
24. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, and the CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
25. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003;18:859-67.
26. Sassi ML, Aman S, Hakala M, Luukkainen R, Risteli J. Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis. Clin Chem Lab Med 2003;41:1038-44.
27. Elmore SM. Pycnodysostosis: a review. J Bone Joint Surg Am 1967;49:153-62.
28. Taylor MM, Moore TM, Harvey JP Jr. Pycnodysostosis: a case report. J Bone Joint Surg Am 1978;60:1128-30.
29. Meredith SC, Simon MA, Laros GS, Jackson MA. Pycnodysostosis: a clinical, pathological, and ultramicroscopic study of a case. J Bone Joint Surg Am 1978;60:1122-7.
30. Nishi Y, Atley L, Eyre DE, Edelson JG, Superti-Furga A, Yasuda T, et al. Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res 1999;14:1902-8.
31. Borman P, Babaoglu S, Gur G, Bingol S, Bodur H. Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin Rheumatol 2007;27:443-7.
32. Schurigt U, Hummel KM, Petrow PK, Gajda M, Stockigt R, Middel P, et al. Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice. Arthritis Rheum 2008;58:422-34.
33. Lazner F, Gowen M, Kola I. An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling. Mol Med Today 1999;5:413-4.
34. Everts V, Korper W, Hoeben KA, Jansen ID, Bromme D, Cleutjens KB, et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 2006;21:1399-408.